Anavex Life Sciences (AVXL) Stock Drops After EMA Recommends Refusal of Blarcamesine: Latest News, Analyst Forecasts, and What’s Next (Dec. 12, 2025)
Anavex Life Sciences Corp. (NASDAQ: AVXL) is back in the spotlight on Friday, December 12, 2025, after European regulators recommended refusing marketing authorization for Blarcamesine Anavex (also known as blarcamesine / ANAVEX®2-73) in Alzheimer’s disease—an outcome that investors had been bracing for since last month’s negative “trend vote” from the EMA’s scientific committee. European Medicines Agency (EMA)+1 The regulatory news hit a stock that has already been trading like a “binary event” biotech: high volatility, heavy short interest, and a valuation that depends largely on the probability of eventual approval and/or additional pivotal evidence in neurodegenerative indications. Finviz+1 Below is
